Sex differences in HIV outcomes in the highly active antiretroviral therapy era: A systematic review

AIDS Research and Human Retroviruses

Volumn 30, Issue 5, 2014, Pages 446-456

  Castilho, Jessica L ^a   Melekhin, Vlada V ^a,b   Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Middle Tennessee Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT DISEASE; AFRICA; ARTICLE; CANADA; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MORTALITY; MULTICENTER STUDY (TOPIC); NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMATIC REVIEW; THAILAND; TRANSGENDERISM; TRANSSEXUALITY; VIRUS TRANSMISSION; HEALTH; HIV INFECTIONS; TREATMENT OUTCOME;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84899867479     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0208     Document Type: Article

References (82)

1. Meditz AL, MaWhinney S, Allshouse A, et al.: Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011;203:442-451
2. Soon GG, Min M, Struble KA, et al.: Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDs 2012;26:444-453
3. Ballesteros-Zebadua P, Villarreal C, Cocho G, Huerta L, and Estrada JL: Differences in HIV-1 viral loads between male and female antiretroviral- untreated Mexican patients. Arch Med Res 2013;44:296-301
4. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, and Quinn TC: Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720-725
5. Moore AL, Kirk O, Johnson AM, et al.: Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr 2003;32:452-461
6. Braga P, Cardoso MR, and Segurado AC: Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDs 2007;21:321-328
7. Chaisson RE, Keruly JC, and Moore RD: Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-756
8. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, and Truman B: Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. New Engl J Med 1987;317:1297-1302
9. Melnick SL, Sherer R, Louis TA, et al.: Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994;272:1915-1921
10. Farzadegan H, Hoover DR, Astemborski J, et al.: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510-1514
11. Prins M, Robertson JR, Brettle RP, et al.: Do gender differences in CD4 cell counts matter? AIDS (London, England) 1999;13:2361-2364
12. Nicastri E, Leone S, Angeletti C, et al.: Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review. J Antimicrob Chemother 2007; 60:724-732
13. May MT, Sterne JA, Costagliola D, et al.: HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: A collaborative analysis. Lancet 2006;368:451-458
14. Moore RD, Keruly JC, and Chaisson RE: Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:29-33
15. Shah S, Smith CJ, Lampe F, et al.: Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: Relationships with gender. HIV Med 2007;8:38-45
16. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Turner MM, and Sterling TR: Hemoglobin may contribute to sex differences in mortality among HIV-infected persons in care. PloS One 2012;7:e44999
17. Etard JF, Ndiaye I, Thierry-Mieg M, et al.: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: A 7-year cohort study. AIDS (London, England) 2006;20:1181-1189
18. Coetzee D, Hildebrand K, Boulle A, et al.: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (London, England) 2004; 18:887-895
19. Mujugira A, Wester CW, Kim S, Bussmann H, and Gaolathe T: Patients with advanced HIV type 1 infection initiating antiretroviral therapy in Botswana: Treatment response and mortality. AIDS Res Hum Retroviruses 2009; 25:127-133
20. Hogg RS, Yip B, Chan KJ, et al.: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577
21. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, and Montaner JS: Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS (London, England) 2003;17:711-720
22. Nachega JB, Hislop M, Dowdy DW, et al.: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006;43:78-84
23. Hoffmann CJ, Fielding KL, Charalambous S, et al.: Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS (London, England) 2010;24:1709-1716
24. Greenbaum AH, Wilson LE, Keruly JC, Moore RD, and Gebo KA: Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS (London, England) 2008;22:2331-2339
25. Lima VD, Hogg RS, Harrigan PR, et al.: Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (London, England) 2007;21:685-692
26. Kitahata MM, Gange SJ, Abraham AG, et al.: Effect of early versus deferred antiretroviral therapy for HIV on survival. New Engl J Med 2009;360:1815-1826
27. Lima VD, Harrigan R, Murray M, et al.: Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS (London, England) 2008;22:2371-2380
28. Moore AL, Sabin CA, Johnson MA, and Phillips AN: Gender and clinical outcomes after starting highly active antiretroviral treatment: A cohort study. J Acquir Immune Defic Syndr 2002;29:197-202
29. Sabine C: AIDS events among individuals initiating HAART: Do some patients experience a greater benefit from HAART than others? AIDS (London, England) 2005; 19:1995-2000
30. Moore RD, Keruly JC, and Chaisson RE: Differences in HIV disease progression by injecting drug use in HIVinfected persons in care. J Acquir Immune Defic Syndr 2004;35:46-51
31. Collazos J, Asensi V, and Carton JA: Sex differences in the clinical, immunological and virological parameters of HIVinfected patients treated with HAART. AIDS (London, England) 2007;21:835-843
32. Mocroft A, Gill MJ, Davidson W, and Phillips AN: Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000;24:475-482
33. Nicastri E, Angeletti C, Palmisano L, et al.: Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS (London, England) 2005;19:577-583
34. Torti C, Lapadula G, Maggiolo F, et al.: Predictors of AIDS-defining events among advanced naive patients after HAART. HIV Clin Trials 2007;8:112-120
35. Hulgan T, Shepherd BE, Raffanti SP, et al.: Absolute count and percentage of CD4 + lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007;195:425-431
36. Thiebaut R, Morlat P, Jacqmin-Gadda H, et al.: Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA). AIDS (London, England) 2000;14:971-978
37. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-129
38. Grabar S, Kousignian I, Sobel A, et al.: Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS (London, England) 2004;18:2029-2038
39. Chene G, Sterne JA, May M, et al.: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003;362:679-686
40. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, and Montaner JS: Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS (London, England) 2006;20:371-377
41. May M, Sterne JA, Sabin C, et al.: Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS (London, England) 2007;21:1185-1197
42. Loutfy MR, Genebat M, Moore D, et al.: A CD4 + cell count 200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010;55: 451-459
43. Taylor-Smith K, Tweya H, Harries A, Schoutene E, and Jahn A: Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J 2010;22:49-56
44. Dou Z, Xu J, Jiao JH, et al.: Gender difference in 2-year mortality and immunological response to ART in an HIVinfected Chinese population, 2006-2008. PloS One 2011;6:e22707
45. Cornell M, Schomaker M, Garone DB, et al.: Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: A multicentre cohort study. PLoS Med 2012;9:e1001304
46. Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, and Fox MP: Gender differences in mortality and CD4 count response among virally suppressed HIVpositive patients. J Womens Health (Larchmt) 2013;22: 113-120
47. Mosha F, Muchunguzi V, Matee M, et al.: Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Pub Health 2013;13:38
48. Peterson I, Togun O, de Silva T, et al.: Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS (London, England) 2011;25:2167-2175
49. van Griensven J and Thai S: Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. Transact R Soc Trop Med Hyg 2011;105:694-703
50. Steele KT, Steenhoff AP, Newcomb CW, et al.: Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana. PloS One 2011;6:e20010
51. May M, Boulle A, Phiri S, et al.: Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: A collaborative analysis of scale-up programmes. Lancet 2010;376:449-457
52. Mutevedzi PC, Lessells RJ, Rodger AJ, and Newell ML: Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PloS One 2011;6:e21795
53. Mills EJ, Bakanda C, Birungi J, Yaya S, and Ford N: The prognostic value of baseline CD4( + ) cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting. AIDS (London, England) 2012; 26:1425-1429
54. Greig J, Casas EC, O'Brien DP, Mills EJ, and Ford N: Association between older age and adverse outcomes on antiretroviral therapy: A cohort analysis of programme data from nine countries. AIDS (London, England) 2012;26(Suppl 1): S31-S37
55. Byakwaga H, Petoumenos K, Ananworanich J, et al.: Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV observational database. J Int Assoc Provid AIDS Care 2013;12:270-277
56. Miro JM, Manzardo C, Mussini C, et al.: Survival outcomes and effect of early vs. deferred cART among HIVinfected patients diagnosed at the time of an AIDS-defining event: A cohort analysis. PloS One 2011;6:e26009
57. Tuboi SH, Brinkhof MW, Egger M, et al.: Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: The antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007;45:52-59
58. Pence BW, Miller WC, Gaynes BN, and Eron JJ Jr: Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007;44:159-166
59. Srasuebkul P, Ungsedhapand C, Ruxrungtham K, et al.: Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Med 2007;8:46-54
60. Pezzotti P, Pappagallo M, Phillips AN, et al.: Response to highly active antiretroviral therapy according to duration of HIV infection. J Acquir Immune Defic Syndr 2001;26:473-479
61. Moore AL, Mocroft A, Madge S, et al.: Gender differences in virologic response to treatment in an HIV-positive population: A cohort study. J Acquir Immune Defic Syndr 2001;26:159-163
62. Kipp W, Alibhai A, Saunders LD, et al.: Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care 2010;22:271-278
63. Crabtree-Ramirez B, Villasis-Keever A, Galindo-Fraga A, del Rio C, and Sierra-Madero J: Effectiveness of highly active antiretroviral therapy (HAART) among HIVinfected patients in Mexico. AIDS Res Hum Retroviruses 2010;26:373-378
64. Routman JS, Willig JH, Westfall AO, et al.: Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clin Infect Dis 2010; 50:574-584
65. Mugavero MJ, Raper JL, Reif S, et al.: Overload: Impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study. Psychosom Med 2009;71:920-926
66. Thorsteinsson K, Ladelund S, Jensen-Fangel S, et al.: Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: A nationwide population-based cohort study. BMC Infect Dis 2012;12:293
67. Klibanov OM, Dolder CR, Assefa F, and Ekwonu TJ: Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic. AIDS Patient Care STDs 2013;27: 205-207
68. Taniguchi T, Grubb JR, Nurutdinova D, et al.: Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care. J Int Assoc Provid AIDS Care 2013;12:138-141
69. Paraskevis D, Touloumi G, Bakoyannis G, et al.: Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: Evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals. AIDS Res Hum Retroviruses 2013;29:461-469
70. Cescon AM, Cooper C, Chan K, et al.: Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multisite Canadian cohort. HIV Med 2011;12:352-360
71. Sangsari S, Milloy MJ, Ibrahim A, et al.: Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: An observational study. BMC Infect Dis 2012;12:22
72. Scherrer AU, Ledergerber B, von Wyl V, et al.: Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011;53:1143-1152
73. Masquelier B, Taieb A, Reigadas S, et al.: Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy. J Antimicrob Chemother 2011;66: 1582-1589
74. Chaiwarith R, Praparattanapan J, Nuntachit N, Kotarathitithum W, Sirisanthana T, and Supparatpinyo K: Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy. Curr HIV Res 2011;9: 82-87
75. Fox MP, Cutsem GV, Giddy J, et al.: Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 2012;60:428-437
76. Wang X, Yang L, Li H, et al.: Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011;9:103-111
77. Lima VD, Bangsberg DR, Harrigan PR, et al.: Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010;55:460-465
78. Gras L, Kesselring AM, Griffin JT, et al.: CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007;45:183-192
79. Florence E, Lundgren J, Dreezen C, et al.: Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003;4:255-262
80. Zhang S, van Sighem A, Gras L, et al.: Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment. Antivir Ther 2010;15:555-562
81. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, and Sterling TR: An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis 2011; 53:952-960
82. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50:1387-1396.